MAIA Biotechnology Market Sentiment

Market sentiment signals for MAIA Biotechnology (MAIA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus— N/A

Short Interest▲ 4.5% short float

Options Flow— N/A

Insider Activity— N/A

Analyst Consensus

—

Options Flow (P/C)

—

Avg Consensus PT

—

Highest Price Target

—

Lowest Price Target

—

Short Interest

4.5%

Declining — Bullish

Insider Activity (30d)

—

Short Interest — % of Float

Insider & Market Activity News

PRO
MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share

Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr.

Benzinga Newsdesk

PRO
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K

Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were purchased by Dr. Smith on

Benzinga Newsdesk

PRO
MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the

Benzinga Newsdesk

PRO
MAIA Biotechnology Announces Independent Director Ms. Adelina Louie Ngar Yee Made An Individual Purchase Of 19,665 Shares, And Warrants For 19,665 Shares Of Common Stock

Original seed investor has remained top MAIA stockholderMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today

Benzinga Newsdesk

PRO
MAIA Biotechnology Announces 170,940 Share Purchase By Director Stan Smith, PhD In A $2.9M Private Placement

Dr. Smith has participated in every MAIA funding roundMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today

Benzinga Newsdesk

MAIA Biotechnology Board Member Awarded $25K Worth of Stock Options

Benzinga Insights

MAIA Biotechnology Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO